TNF and Crohn disease: Patients aged 18 to 80 years, diagnosed with moderate-to-severe Crohn’s disease (CD) at least three months prior and having an inadequate response or intolerance to corticosteroids, immunosuppressants and/or anti-TNF, were selected for the trial.